Citigroup
CTXR icon

Citigroup’s Citius Pharmaceuticals CTXR Stock Holding History

Citigroup’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,228
Closed -$4.71K – 5825
2026
Q1 		$4.71K Buy
5,228
+4,385
+520% +$3.54K ﹤0.01% 5275
2025
Q4 		$655 Sell
843
-774
-48% -$968 ﹤0.01% 5572
2025
Q3 		$2K Buy
+1,617
New +$2.25K ﹤0.01% 5480
2025
Q1 		– Sell
-73
Closed -$292 – 5663
2024
Q4 		$292 Sell
73
-565
-89% -$3.81K ﹤0.01% 5650
2024
Q3 		$7.98K Sell
638
-82
-11% -$1.38K ﹤0.01% 5312
2024
Q2 		$10.5K Sell
720
-276
-28% -$4.95K ﹤0.01% 5131
2024
Q1 		$22.3K Buy
996
+288
+41% +$5.26K ﹤0.01% 4999
2023
Q4 		$13.4K Buy
708
+706
+35,300% +$13.4K ﹤0.01% 5121
2023
Q3 		$42 Sell
2
-1,462
-100% -$34.7K ﹤0.01% 5538
2023
Q2 		$43.9K Sell
1,464
-1,313
-47% -$43.2K ﹤0.01% 4713
2023
Q1 		$81.2K Buy
+2,777
New +$80.1K ﹤0.01% 4105
2022
Q3 		– Sell
-44
Closed -$1K – 5903
2022
Q2 		$1K Sell
44
-389
-90% -$10.7K ﹤0.01% 5999
2022
Q1 		$19K Sell
433
-720
-62% -$28.4K ﹤0.01% 5170
2021
Q4 		$44K Buy
1,153
+619
+116% +$28.1K ﹤0.01% 5129
2021
Q3 		$27K Buy
534
+318
+147% +$16K ﹤0.01% 5082
2021
Q2 		$19K Buy
+216
New +$13K ﹤0.01% 5321

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MFS
Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM

Citigroup's CTXR Position: Q2 2026 in Review

Citigroup sold out of Citius Pharmaceuticals (CTXR) in Q2 2026, closing a stake of 5,228 shares — an estimated $4.71K sold.

Citigroup first reported a position in CTXR in Q2 2021 and held it in 16 quarters. The position peaked at $81.2K in Q1 2023. 43 funds tracked by Wall St. Rank hold CTXR as of Q2 2026.

  • Citigroup reported no remaining Citius Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Citigroup sold 5,228 Citius Pharmaceuticals shares in Q2 2026, an estimated $4.71K.
  • Citigroup first reported a position in Citius Pharmaceuticals in Q2 2021 and held it in 16 quarters.
  • Citigroup's Citius Pharmaceuticals position peaked at $81.2K in Q1 2023.
  • 43 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.